P21 (P021): what it is and what the evidence says
A peptidomimetic derived from a fragment of ciliary neurotrophic factor, designed to cross the blood-brain barrier.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
The brain adapts by forming and strengthening connections. Neurotransmitters take part in that conversation, along with factors that help neurons survive and grow. Compounds in this group are studied for their relationship with focus, memory, mood or neuroprotection — and it is worth saying plainly that this is the area where claims are most exaggerated and where human evidence is thinnest.
What it is studied for
Advertised as a nootropic.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
Zero studies in humans. P021 is a peptidomimetic compound derived from a fragment of ciliary neurotrophic factor. All the evidence is in mice and rats. It has never entered published phase I clinical trials.
The limitation that matters most
Unlike the Russian bioregulators, the preclinical science here is solid and published in serious peer-reviewed journals, but that does not change the fact that it has NEVER been tested in a human being. Mistaking a good result in a transgenic mouse for clinical efficacy is the central error made when it is sold as a nootropic.
Regulatory status
Not approved in any jurisdiction. A preclinical research compound.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Serious preclinical science, but never tested in a human being.
Memory or attention problems that cause worry deserve a neurological workup, since treatable causes are identified through clinical testing rather than through an experimental compound.
What this page cannot give you
A reference page can take you this far. You know what P21 (P021) is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a diploma with a verifiable folio, a record to track how you progress, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compoundpreclinical Neurobiol Aging · 2014 · PMID 24702821 →
- Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's diseasepreclinical Neurobiol Dis · 2014 · PMID 25046994 →
- Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compoundpreclinical Alzheimers Res Ther · 2017 · PMID 28655344 →
- Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in micepreclinical Alzheimers Res Ther · 2020 · PMID 32854771 →
- Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's diseasereview Mol Neurodegener · 2016 · PMID 27400746 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for P21 (P021) or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is P21 (P021)?
A peptidomimetic derived from a fragment of ciliary neurotrophic factor, designed to cross the blood-brain barrier. It is studied within the area of cognitive.
Is there human evidence for P21 (P021)?
Zero studies in humans. P021 is a peptidomimetic compound derived from a fragment of ciliary neurotrophic factor. All the evidence is in mice and rats. It has never entered published phase I clinical trials.
Is it approved by any health agency?
Not approved in any jurisdiction. A preclinical research compound.
What is the dose of P21 (P021)?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what P21 (P021) is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.